Efficacy

Efficacy of Zejula (Niraparib) in Gynecological Cancer

Zejula (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of certain types of gynecological cancers, including ovarian, fallopian tube, and primary peritoneal cancer. It is particularly effective in patients who have a specific genetic marker, the BRCA mutation, although its use has been expanded to include a broader patient population. Clinical trials have demonstrated that niraparib significantly improves progression-free survival in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

In a pivotal phase 3 trial known as the NOVA trial, niraparib was shown to be effective as a maintenance treatment, extending the time patients lived without their cancer progressing. For patients with a germline BRCA mutation, the median progression-free survival was significantly longer compared to placebo. Moreover, even in the non-germline BRCA mutant cohort, niraparib still provided a clinically meaningful increase in progression-free survival, indicating its efficacy in a wider range of patients with these gynecological cancers.

Efficacy of Orserdu (Elacestrant) in Gynecological Cancer

Orserdu (elacestrant) is a novel oral selective estrogen receptor degrader (SERD) that is being investigated for the treatment of estrogen receptor-positive (ER+) gynecological cancers, such as endometrial cancer. While elacestrant is not yet widely approved for use, clinical trials are ongoing to determine its efficacy in patients with advanced or metastatic ER+ breast cancer, which may provide insights into its potential use in gynecological cancers.

The efficacy of Orserdu in gynecological cancers is currently being evaluated, and there is limited published data specifically for this use. However, the mechanism of action of elacestrant, which involves targeting and degrading estrogen receptors, suggests a potential therapeutic benefit in ER+ gynecological cancers. As clinical trials progress, more data will become available to establish the efficacy and safety profile of Orserdu for patients with these types of cancers.